Latest news
Latest news
Johnson & Johnson named to Fortune’s 2024 America’s Most Innovative Companies list
The company’s drive to develop novel solutions for the world’s toughest healthcare challenges has earned it a spot on Fortune’s second annual list.
What to know about low vision
Low vision isn’t the same as blindness, but navigating daily life with it is still challenging. For Low Vision Awareness Month, learn the facts—plus, the promising treatment innovations that are in the works.
More from Johnson & Johnson
Meet 3 leaders who are breaking new ground for women in healthcare
For International Women’s Day, celebrate the achievements of these amazing female scientists and researchers at Johnson & Johnson.
What is an orphan drug?
The need for these rare disease therapies is strong, and access to them can be lifesaving. Here’s how Johnson & Johnson is innovating to help give patients options.
3 health advocates; 1 Johnson & Johnson program that offers empowerment and connection
In the quest to solve the toughest health challenges, innovating therapies and finding treatments are essential—but so is supporting the patients living with these diseases. That’s exactly why Johnson & Johnson launched HealtheVoices a decade ago.
What is cardiac ablation?
For American Heart Month, learn how Johnson & Johnson is innovating to help treat the millions of people who are living with atrial fibrillation and other conditions that cause an irregular heartbeat.
Do you know what heart failure is? (Hint: It’s probably not what you think)
For American Heart Month, learn about the advances Johnson & Johnson is making to help turn heart failure into heart recovery for the millions of adults in the U.S. living with the condition, which occurs when the heart muscle isn’t able to pump blood as well as it should.
Could we be on the cusp of catching Alzheimer’s before it starts?
The key to slowing cognitive decline is diagnosing the disease as early as possible. And that’s exactly what Johnson & Johnson scientists are relentlessly pursuing.
Press releases
CERENOVUS Expands Minimally Invasive Stroke Care Innovation with New Liquid Embolic System Procedural Set
CERENOVUS launches TRUFILL™ n-BCA Liquid Embolic System Procedural Set Design Addresses Real-World Challenges in Treatment of Hemorrhagic Stroke
Johnson & Johnson’s nipocalimab granted U.S. FDA Fast Track designation to reduce the risk of fetal neonatal alloimmune thrombocytopenia (FNAIT) in alloimmunized pregnant adults
FNAIT is a rare disease that occurs when a pregnant person’s immune system attacks fetal platelets, resulting in the risk of internal bleeding, which can be life threatening to the fetus or newborn The Phase 3 FREESIA program is underway and nipocalimab is the only investigational therapy currently reported to be in clinical development for the treatment of FNAIT
U.S. FDA Approves OPSYNVI® (macitentan and tadalafil) as the First and Only Once-Daily Single-Tablet Combination Therapy for Patients with Pulmonary Arterial Hypertension (PAH)
OPSYNVI® combines two proven treatments with established efficacy and safety profiles into one tablet to be taken once daily, offering an option that helps to support the implementation of clinical guideline recommendations for early use of combination therapy.1 The comprehensive PAH portfolio at Johnson & Johnson now includes treatments that address all three foundational and guideline-recommended pathways for this rare, progressive disease.2 Approval is based on the results from the pivotal Phase 3 A DUE study, which met its co-primary endpoints, demonstrating significant pulmonary hemodynamic improvement.1
U.S. FDA Approves EDURANT® PED (rilpivirine) for Certain Pediatric Patients Living with HIV-1
This approval offers a new HIV-1 treatment option for children in the U.S. at least 2 years of age, weighing 14 kg – 25 kg and living with HIV
Johnson & Johnson MedTech working with NVIDIA to scale AI for surgery
Johnson & Johnson MedTech is working with NVIDIA on how its technologies can accelerate secure, real-time analysis of surgical data at the edge Johnson & Johnson MedTech will enable AI-based model development and application deployment, providing a path to scale within its connected digital ecosystem for surgery
RYBREVANT® (amivantamab-vmjw) data at ELCC advance Johnson & Johnson’s ambition to transform the standard of care for patients with EGFR-mutated non-small cell lung cancer
Featured data include new results from the Phase 3 MARIPOSA study, which has received U.S. FDA Priority Review, and the Phase 1b PALOMA study of subcutaneous amivantamab